Overview
Cisplatin-induced kidney disorder, often manifesting as acute kidney injury (AKI), is a significant adverse effect associated with the use of cisplatin, a widely utilized chemotherapeutic agent for treating various malignancies including testicular, ovarian, and lung cancers. This nephrotoxicity primarily arises due to the accumulation of platinum compounds in renal tubular cells, leading to cellular damage and impaired renal function. Patients undergoing cisplatin therapy, particularly those receiving high cumulative doses or concomitant nephrotoxic agents, are at risk. Early recognition and management are crucial to mitigate severe complications and preserve renal function, impacting treatment efficacy and patient survival rates 1.Pathophysiology
The nephrotoxicity induced by cisplatin stems from its accumulation in the proximal renal tubules, where it forms reactive oxygen species (ROS) and disrupts cellular homeostasis. At a molecular level, cisplatin binds to intracellular proteins and DNA, inducing oxidative stress and apoptosis in tubular epithelial cells. This cellular damage triggers an inflammatory response, characterized by the release of cytokines and chemokines, further exacerbating tubular injury. The resultant cellular dysfunction impairs reabsorption and secretion processes, leading to tubular obstruction and decreased glomerular filtration rate (GFR). Over time, these processes can progress to chronic kidney disease if not adequately managed 1.Epidemiology
The incidence of cisplatin-induced nephrotoxicity varies based on cumulative dose, frequency of administration, and patient-specific factors such as age, pre-existing renal impairment, and concurrent medications. Studies suggest that approximately 20-50% of patients receiving cisplatin develop some degree of renal dysfunction, with higher doses correlating strongly with increased risk. Younger patients generally tolerate higher doses better, but elderly patients and those with pre-existing renal conditions are disproportionately affected. Geographic and ethnic variations are less documented, but comorbidities and healthcare access likely play significant roles in observed differences 1.Clinical Presentation
Patients typically present with nonspecific symptoms initially, such as fatigue, decreased urine output, and mild elevations in serum creatinine levels. More pronounced signs include oliguria or anuria, hypertension, and electrolyte imbalances (particularly hypokalemia and hyperkalemia). Red-flag features that necessitate urgent evaluation include rapid deterioration in renal function, severe metabolic acidosis, and signs of uremic syndrome like confusion or seizures. Early recognition of these symptoms is critical for timely intervention to prevent irreversible kidney damage 1.Diagnosis
The diagnosis of cisplatin-induced kidney disorder involves a combination of clinical assessment and laboratory evaluations. Key diagnostic criteria include:Serum Creatinine and GFR: Elevated serum creatinine levels (typically >1.5 times baseline) and decreased GFR (<60 mL/min/1.73 m2) 1.
Urine Analysis: Presence of proteinuria, hematuria, and casts indicative of tubular injury 1.
Imaging: Renal ultrasound may show reduced cortical echogenicity or other signs of acute tubular injury, though it is not always definitive 1.
Differential Diagnosis: Exclude other causes of AKI such as dehydration, sepsis, other nephrotoxic drugs (e.g., aminoglycosides, nonsteroidal anti-inflammatory drugs), and underlying renal diseases 1.Differential Diagnosis
Dehydration: Typically presents with concentrated urine and responds to fluid resuscitation.
Sepsis: Characterized by systemic inflammatory response syndrome with signs beyond renal dysfunction alone.
Drug-Induced Nephrotoxicity (Other Agents): Specific patterns in urine analysis or history of concurrent nephrotoxic drug use can differentiate 1.Management
First-Line Management
Fluid Management: Maintain adequate hydration, often requiring intravenous fluids to maintain urine output >0.5 mL/kg/hr 1.
Monitoring: Frequent monitoring of serum creatinine, electrolytes, and urine output 1.Second-Line Management
Discontinue Cisplatin: Temporarily halt cisplatin administration if significant renal impairment occurs 1.
Renal Protective Agents: Use of agents like sodium thiosulfate preemptively or post-exposure to mitigate platinum accumulation (though efficacy varies) 1.Refractory or Specialist Escalation
Dialysis: Initiate dialysis for severe cases with anuria, hyperkalemia, or metabolic acidosis refractory to medical management 1.
Consultation: Nephrology consultation for complex cases, especially those requiring long-term management or renal replacement therapy 1.Contraindications
Severe Pre-existing Renal Impairment: High-dose cisplatin may be contraindicated in patients with baseline GFR <60 mL/min/1.73 m2 1.Complications
Chronic Kidney Disease: Prolonged exposure to cisplatin can lead to irreversible renal damage requiring long-term monitoring and potential dialysis 1.
Electrolyte Imbalances: Persistent hypokalemia or hyperkalemia necessitates close electrolyte monitoring and correction 1.
When to Refer: Urgent nephrology consultation is warranted for persistent oliguria, rapid decline in renal function, or refractory electrolyte imbalances 1.Prognosis & Follow-Up
The prognosis varies based on the severity and duration of renal impairment. Patients who recover renal function within weeks typically have a favorable outcome, whereas those with prolonged dysfunction may face chronic kidney disease. Key prognostic indicators include baseline renal function, cumulative cisplatin dose, and timely intervention. Follow-up should include regular monitoring of renal function (serum creatinine, GFR) every 1-3 months for at least the first year post-treatment 1.Special Populations
Elderly Patients: Higher susceptibility to nephrotoxicity; dose adjustments and closer monitoring are essential 1.
Pre-existing Renal Impairment: Increased risk; careful dose titration and renal function monitoring are critical 1.
Pediatrics: Less data available, but similar principles apply with careful dose adjustments based on body surface area 1.Key Recommendations
Monitor Renal Function Regularly: Measure serum creatinine and estimate GFR before each cisplatin cycle and more frequently if clinical suspicion arises 1 (Evidence: Strong).
Maintain Adequate Hydration: Ensure intravenous fluid administration to maintain urine output >0.5 mL/kg/hr 1 (Evidence: Strong).
Consider Preemptive Renal Protective Agents: Evaluate the use of sodium thiosulfate in high-risk patients 1 (Evidence: Moderate).
Discontinue Cisplatin if AKI Develops: Temporarily halt cisplatin administration in cases of significant renal impairment 1 (Evidence: Strong).
Initiate Dialysis for Severe Cases: Consider dialysis for patients with anuria, hyperkalemia, or metabolic acidosis unresponsive to medical management 1 (Evidence: Moderate).
Consult Nephrology Early: Seek specialist input for complex cases or persistent renal dysfunction 1 (Evidence: Expert opinion).
Adjust Doses Based on Baseline Renal Function: Reduce cisplatin dose in patients with baseline GFR <60 mL/min/1.73 m2 1 (Evidence: Moderate).
Long-Term Monitoring: Schedule follow-up renal function tests every 1-3 months for at least one year post-treatment 1 (Evidence: Moderate).
Avoid Concurrent Nephrotoxic Agents: Minimize use of other nephrotoxic drugs when possible 1 (Evidence: Expert opinion).
Evaluate for Electrolyte Imbalances: Regularly monitor and correct electrolyte disturbances, particularly potassium levels 1 (Evidence: Strong).References
1 Grélot L, Girod V, Dapzol J, Maffrand JP, Serradeil-Le Gal C. A nonpeptide vasopressin V(1a) receptor antagonist, SR 49059, does not prevent cisplatin-induced emesis in piglets. Fundamental & clinical pharmacology 2001. link